Skip to main navigation Skip to search Skip to main content

Fibroneer - PF-ILD A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)

  • Glaspole, Ian (Primary Chief Investigator (PCI))
  • Symons, Karen (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date2/02/23 → 1/02/25

Keywords

  • Clinical Trials
  • Respiratory diseases
  • Fibroneer

Clinical Trial Phase

  • Phase III (a & b)